Aaron G.L. Fletcher sold $189k of LTRN
owner at Lantern Pharma Inc.. 30,000 shares at an average of $6.30, traded May 23, 2024, filed May 28, 2024.
Score components
- +12Role10% owner
- +12Trade size$189k at market
- +10Share of holdings soldSold 50% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-24-065616, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 23, 2024 | SOpen-market sale Common Stockindirect: By Bios Fund II NT, LP | -930 | $6.25 | $5,813 | 59,326 | May 28, 2024 |
| May 24, 2024 | SOpen-market sale Common Stockindirect: By Bios Fund II NT, LP | -1,859 | $6.33 | $12k | 57,467 | May 28, 2024 |
| May 23, 2024 | SOpen-market sale Common Stockindirect: By Bios Fund II QP, LP | -6,944 | $6.25 | $43k | 443,174 | May 28, 2024 |
| May 24, 2024 | SOpen-market sale Common Stockindirect: By Bios Fund II QP, LP | -13,888 | $6.33 | $88k | 429,286 | May 28, 2024 |
| May 23, 2024 | SOpen-market sale Common Stockindirect: By Bios Fund II, LP | -2,126 | $6.25 | $13k | 135,706 | May 28, 2024 |
| May 24, 2024 | SOpen-market sale Common Stockindirect: By Bios Fund II, LP | -4,253 | $6.33 | $27k | 131,453 | May 28, 2024 |
Related signals
Other insiders at Lantern Pharma Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 51Moderate | Lantern Pharma Inc. | D Jeffrey Keyser director | $100k 48,544 shares | +106% | |
| 49Moderate | Lantern Pharma Inc. | Lee Troy Schalop director | $100k 48,544 shares | - | |
| 42Moderate | Lantern Pharma Inc. | Aaron G.L. Fletcher owner | $208k 61,613 shares | -30% | |
| 35Weak | Lantern Pharma Inc. | Aaron G.L. Fletcher owner | $124k 40,000 shares | -20% | |
| 42Moderate | Lantern Pharma Inc. | Leslie W. Kreis owner | $208k 61,613 shares | -30% | |
| 35Weak | Lantern Pharma Inc. | Leslie W. Kreis owner | $124k 40,000 shares | -20% | |
| 41Moderate | Lantern Pharma Inc. | Aaron G.L. Fletcher owner | $168k 56,237 shares | -26% | |
| 41Moderate | Lantern Pharma Inc. | Leslie W. Kreis owner | $168k 56,237 shares | -26% | |
| 42Moderate | Lantern Pharma Inc. | Leslie W. Kreis owner | $189k 30,000 shares | -50% | |
| 60Notable | Lantern Pharma Inc. | Aaron G.L. Fletcher owner | $676k 144,000 shares | -196% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.